Abstract
Background
S-1(TS-1®), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan. A nationwide post-marketing survey for safety was carried out after its approval. The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the post-marketing survey from our institution.
Methods
Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East. S-1 was administered at 80 mg/m2/day for 4 weeks, followed by a 2-week rest, repeated every 6 weeks until disease progression, unacceptable toxicity, or the patient's refusal.
Results
Of the 51 patients, 41 (80%) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration. The median number of treatment courses was five. Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10% or fewer patients, and no treatment-related deaths occurred. In the 47 patients with evaluable lesions, there were 2 complete responses and 18 partial responses, with a response rate of 43%. With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33%, respectively. The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response.
Conclusion
S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.
Article PDF
Similar content being viewed by others
References
AM Murad FF Santiago A Petroianu et al. (1993) ArticleTitleModified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37–41 Occurrence Handle8508427 Occurrence Handle1:STN:280:ByyB1cvlvFM%3D
B Glimelius K Hoffman U Haglund et al. (1994) ArticleTitleInitial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189–90 Occurrence Handle8186165 Occurrence Handle1:STN:280:ByuB2c3mvVY%3D
S Pyrhonen T Kuitunen P Nyandoto et al. (1995) ArticleTitleRandomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587–91 Occurrence Handle7533517 Occurrence Handle1:STN:280:ByqC1cnjvVA%3D
T Shirasaka Y Shimamoto H Ohshimo et al. (1996) ArticleTitleDevelopment of a novel form of an oral fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulations Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
Y Sakata A Ohtsu N Horikoshi et al. (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur −0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano et al. (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 1st English Ed. In: Japanese Research Society for Gastric Cancer, editors. Tokyo: Kanehara; 1995
InstitutionalAuthorNameWorld Health Organization (1979) WHO Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48 World Health Organization Geneva
A Ohtsu N Boku F Nagishima et al. (2001) ArticleTitleA phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (AGC) (abstract) Proc Am Soc Clin Oncol 20 165
Y Inuyama A Kida M Tsukuda et al. (2001) ArticleTitleLate phase II study of S-1 in patients with advanced head and neck cancer (in Japanese). Gan to Kagakuryouhou Jpn J Cancer Chemother 28 1381–90 Occurrence Handle1:STN:280:DC%2BD3Mrntl2isg%3D%3D
A Ohtsu H Baba Y Sakata et al. (2000) ArticleTitlePhase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma Br J Cancer 83 141–5 Occurrence Handle10901361 Occurrence Handle1:CAS:528:DC%2BD3cXltl2mur8%3D
M Sano T Saeki S Takashima et al. (2000) ArticleTitleLate phase II study of S-1 in patients with advanced and/or recurrent breast cancer (abstract) Proc Am Soc Clin Oncol 19 105
M Kawahara K Furuse Y Segawa et al. (2001) ArticleTitlePhase II study of S-1, a novel oral fluorouracil in advanced non-small-cell lung cancer Br J Cancer 85 939–43 Occurrence Handle11592762 Occurrence Handle10.1038/sj.bjc.6692031 Occurrence Handle1:CAS:528:DC%2BD3MXot1SktLg%3D
Nagashima F, Ohtsu A, Boku N, et al. Japanese nation-wide post marketing survey of S-1 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2002;21:(abstract no. 2228)
M Ohkuwa A Ohtsu N Boku et al. (2000) ArticleTitleLong-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials Gastric Cancer 3 145–50 Occurrence Handle11984728
A Ohtsu Y Shimada K Shirao et al. (2003) ArticleTitleRandomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54–9 Occurrence Handle12506170 Occurrence Handle10.1200/JCO.2003.04.130 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWru7k%3D
M Yoshida N Boku A Ohtsu et al. (2001) ArticleTitleCombination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice Gastric Cancer 4 144–9 Occurrence Handle11760080 Occurrence Handle1:CAS:528:DC%2BD38XntFWnsQ%3D%3D
M Tahara A Ohtsu N Boku et al. (2001) ArticleTitleSequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study Gastric Cancer 4 212–8 Occurrence Handle11846065 Occurrence Handle10.1007/s10120-001-8012-x Occurrence Handle1:CAS:528:DC%2BD38XislCksbc%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawai, H., Ohtsu, A., Boku, N. et al. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer 6 (Suppl 1), 19–23 (2003). https://doi.org/10.1007/s10120-003-0216-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0216-9